Effect of PolyGlycopleX (PGX) Consumption on Blood Lipid Profiles in Healthy, Low CVD Risk Overweight Adults

Raised blood lipid levels are associated with a risk of a cardiovascular disease (CVD). Moderate reductions in several CVD factors such as total, low-density lipoprotein (LDL) cholesterol and non-high-density lipoprotein (non-HDL) cholesterol concentrations may be more effective in reducing overall...

Full description

Saved in:
Bibliographic Details
Published in:Nutrients 2019-03, Vol.11 (4), p.717
Main Authors: Solah, Vicky A, Kerr, Deborah A, Irawati, Deasy, Hunt, Wendy, Meng, Xingqiong, Gahler, Roland J, Fenton, Haelee K, Johnson, Stuart K, James, Anthony P, Wood, Simon
Format: Article
Language:English
Subjects:
Adult
Aged
Alginates - administration & dosage
Apolipoproteins
Barley
Blood
blood lipids
Blood pressure
Body weight
cardiovascular
Cardiovascular Diseases - etiology
Cardiovascular Diseases - prevention & control
Chemical bonds
Cholesterol
Cholesterol - blood
Cholesterol, LDL - blood
Diabetes
Dietary fiber
Dietary Supplements
Disease control
disease risk
Drug Combinations
Epidemiology
Fasting
Fatty acids
Female
Gastrointestinal system
Gastrointestinal tract
Health care
Health sciences
High density lipoprotein
Humans
Hydration
Innovations
Lipids
Lipids - blood
Low density lipoprotein
Male
Medicine
Metabolic syndrome
Middle Aged
Nutrition
Obesity
Overweight - blood
Overweight - complications
Polysaccharides, Bacterial - administration & dosage
Public health
Risk Factors
Single-Blind Method
Treatment Outcome
Vascular diseases
Viscosity
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Raised blood lipid levels are associated with a risk of a cardiovascular disease (CVD). Moderate reductions in several CVD factors such as total, low-density lipoprotein (LDL) cholesterol and non-high-density lipoprotein (non-HDL) cholesterol concentrations may be more effective in reducing overall risk than a major reduction in just one. A blind, randomised controlled trial was conducted with 120 healthy overweight (BMI 25⁻30) adults aged 25⁻70 years who were non-smokers, not diabetic and of low risk of cardiovascular disease, as assessed by the Framingham risk equation. Participants consumed 4.5 g PolyGlycopleX (PGX) as softgel capsules (PGXS) or 5 g PGX granules (PGXG) or 5 g rice flour (RF) with meals three times a day for 12 weeks. Total, LDL and non-HDL cholesterol were all significantly reduced (-6%, -5% and -3.5%, respectively) post the PGX granule treatment; however, PGX in softgel capsule form did not affect blood lipid profiles. Daily consumption of PGX granules in overweight low CVD risk adults produced lipid changes indicating a CVD preventative benefit.
ISSN:2072-6643
2072-6643
DOI:10.3390/nu11040717